A regulatory milestone for Avingtrans (LSE:AVG)'s imaging unit Adaptix headlined a busy session for health and biotech small caps, while Novo Nordisk's latest Wegovy sub-analysis added clinical weight to the obesity drug's long-term efficacy story. IXICO (AIM:IXI) and Physiomics each posted company updates that moved their shares in opposite directions.
Adaptix secures CE mark for Ortho350 imaging device
Avingtrans (LSE:AVG), the engineering and medical imaging group, saw its subsidiary Adaptix receive CE certification for the Adaptix Ortho350, clearing the path for commercial sales across the UK and European markets. The approval marks a significant step for Adaptix's go-to-market strategy, removing the principal regulatory barrier to revenue generation in two of its core target geographies. Avingtrans shares edged up 1.35% to 648.61p on the news.
Novo Nordisk's STEP UP data shows 27.7% weight loss in early Wegovy responders
A sub-analysis of the STEP UP trial, presented at the European Congress on Obesity, showed that patients who achieved at least 15% weight loss by week 24 on semaglutide 7.2 mg went on to lose an average of 27.7% of body weight by week 72. A separate analysis from the same dataset found that the majority of weight lost was fat rather than lean muscle mass, a finding with meaningful implications for the clinical profile of higher-dose semaglutide. Novo Nordisk A/S is not listed on the UK small-cap market, but the data carries relevance for the broader obesity therapeutics landscape in which several domestic names operate.
IXICO upgrades neuroimaging platform to boost throughput and precision
IXICO (AIM:IXI) released an upgraded version of its neuroimaging processing platform, with the new iteration delivering faster image-reading speeds, improved precision, and a technical foundation designed to support licensing and partnership deployments, including through its recently announced Medidata collaboration. The upgrade positions IXICO to scale its technology beyond its own trial services business and into a broader partner ecosystem. Shares rose 4.0% to 6.89p.
Physiomics brings in AstraZeneca programme veteran as consultant
Physiomics (AIM:PYC) appointed Stewart Williams as a consultant to support its senior leadership transition. Williams brings more than 30 years' experience in transformation roles, and currently serves as Head of Planning on AstraZeneca's AXIAL programme, a capital project valued at approximately $2 billion. The appointment is framed as a bridge measure during a period of organisational change at the computational biology firm. Shares fell 8.66% to 0.58p on the day.
